Skip to main content

Table 2 Preclinical experiments and clinical trials in promising cancer target of CD112/CD112R

From: The CD112R/CD112 axis: a breakthrough in cancer immunotherapy

Tumor types Treatment Key results References
melanoma and colon cancer CD112R deletion;
anti-CD112R blocking Ab, alone or in combination with anti-PD-L1 inhibitors
Increased the CD8+ T cells immune cell tumor infiltration; improve the antitumor body defense and suppress refractory tumor progression [31]
endometrial, ovarian, kidney, head and neck, and lung cancers single treatment and combination of anti-CD112R, anti-PD-1, and anti-TIGIT Enhanced CD8+ T-cell effector in cancers [33]
breast cancer Combination of CD112R and TIGIT mAbs Boosted cytokine production by NK cells and improved NK cell cytotoxicity and tumor-killing effect [26]
primary peritoneal
carcinoma and microsatellite-stable colorectal cancer
single-agent anti-CD112R (COM701), combination with anti-PD-L1 inhibitor nivolumab The clinical benefit rate was 69% in the COM701 cohort and 75% in the combination group; Pelvic metastases have regressed notably. [62, 63]